Blog Hero

On a GLP-1? What the new FDA eye warning actually means

Book Online

If you take Ozempic, Wegovy, Mounjaro, Zepbound, or a similar medication, you’ve probably seen the headlines linking it to vision loss.

Here’s what you need to know.

What the FDA Did

On November 9, the FDA told the makers of every GLP-1 medication to add a warning to their labels about a rare eye condition called NAION (non-arteritic anterior ischemic optic neuropathy), sometimes referred to as an “eye stroke” in news coverage. (1) The warning covers the whole class, including semaglutide, tirzepatide, liraglutide, and dulaglutide, whether the prescription is for diabetes or for weight loss.

The FDA’s own wording is careful: a potential increased risk of a rare condition.

What NAION Is

Optic neuropathy is damage to the optic nerve, the cable that carries what you see from the eye to the brain. Ischemic means the damage comes from too little blood flow. Anterior means it happens at the front of the nerve, where it meets the eye. Non-arteritic means it isn’t caused by inflamed arteries, which is a separate and rarer condition.

In plain terms: blood flow to the front of the optic nerve drops, and vision in one eye dims or blurs suddenly, without pain. People often notice it when they wake up. The loss can be permanent, which is why it’s taken seriously even though it’s uncommon.

NAION was around long before these medications. Among adults over 50, somewhere between 2 and 10 people in every 100,000 develop it each year. (1) Diabetes, high blood pressure, and sleep apnea all raise the odds, and those are the same conditions many people on a GLP-1 are being treated for. That overlap is a big part of why the question is hard to settle.

The Risk Is Small

In the clinical trials the FDA reviewed, covering more than 134,000 patients, NAION occurred in about 6 of every 100,000 people per year on a GLP-1, compared with about 4 on a placebo or a different medication. (1)

Two days after the FDA’s announcement, the American Academy of Ophthalmology and the North American Neuro-Ophthalmology Society responded jointly. Their summary: “NAION is rare, any added risk appears small, and it has not been established that these medications cause NAION.” (2)

What Not to Do

Don’t stop your medication because of this.

These medications treat serious conditions, and stopping one on your own carries real risks. The specialists’ guidance is direct: any decision to stop belongs in a conversation with the doctor who prescribed it. (2)

What to Do Instead

Know the one symptom that matters. Sudden, painless vision loss in one eye: a dim or hazy patch, a blind spot, part of your view missing. Don’t wait to see if it clears. Call us the same day, and if we’re closed, go to an emergency room. That holds for anyone, on any medication.

If you have diabetes, keep your regular diabetic eye exams. They matter more than this warning does. If you’ve recently started a GLP-1, tell us. We may want to see you a little sooner than usual. (3)

If you’ve ever had NAION, or have lost vision in one eye, talk with your doctors before starting one of these medications. (2, 4)

Tell us what you take. At your next visit, mention your GLP-1 the way you’d mention any other prescription. It helps us know what to look for.

The Short Version

A warning label on a medication you rely on is unsettling. This one asks very little of you: know one symptom, keep your regular exams, and leave your prescription alone unless your doctor says otherwise.

Questions about your own eyes? Call us. And if you’re due for your annual exam, that’s reason enough to come in.

Schedule an eye exam. Call 415-673-2020 or use our instant online booking tool.

— Your Optometry Team at Acuity Vision Optometry Boutique

For personalized service and vibrant neighborhoods, support local independent businesses like Acuity Vision Optometry Boutique!

References

  1. U.S. Food and Drug Administration. “FDA Requires Safety Labeling Changes for Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Due to Potential Increased Risk of Rare But Serious Eye Condition.” November 9, 2026. https://www.fda.gov/drugs/drug-safety-communications/fda-requires-safety-labeling-changes-glucagon-peptide-1-receptor-agonists-glp-1-ras-due-potential
  2. American Academy of Ophthalmology and North American Neuro-Ophthalmology Society. “Here’s What You Need to Know About FDA’s New GLP-1 Warning.” November 11, 2026. https://www.aao.org/newsroom/news-releases/detail/here-s-what-you-need-to-know-about-fda-s-new-glp-1
  3. American Academy of Ophthalmology. “Glucagon-Like Peptide-1 Receptor Agonists and Diabetic Retinopathy: A Statement from the American Academy of Ophthalmology.” November 2026. https://www.aao.org/education/clinical-statement/glucagon-like-peptide-1-receptor-agonists-diabetic
  4. DeParis SW, Oke I, Gaier ED, et al. “Glucagon-Like Peptide-1 Receptor Agonists and the Risk of Non-Arteritic Anterior Ischemic Optic Neuropathy: A Consensus Statement by NANOS and the American Academy of Ophthalmology.” May 2026. https://www.aao.org/education/clinical-statement/glucagon-like-peptide-1-receptor-agonists-risk-of-

Written by Dr. Lyndi Fandino Schmidt

Dr. Lyndi Schmidt founded Acuity Vision Optometry Boutique in 2004. Read Dr. Schmidt's full biography.
instagram facebook facebook2 pinterest twitter google-plus google linkedin2 yelp youtube phone location calendar share2 link star-full star star-half chevron-right chevron-left chevron-down chevron-up envelope fax